Skin boosters: what the scientific evidence shows and doesn't

"Do skin boosters work?" looks like a question with a short answer, but it does not have one. The honest answer is: it depends on what you call working, which product, which technique, in whom, and measured by whom. The literature on the topic has grown, and with it has grown the gap between what studies can state and what marketing says. The professional's place is the middle ground: know the data, recognize the limits, and translate that for the patient without exaggeration.

This page does not present numerical results and does not replace reading the papers. The goal is to teach how to read what exists on the skin booster, which measures are commonly used, where the methodological weaknesses are, and how the conversation with the patient should reflect this.

What questions does the literature try to answer?

Studies on skin boosters are generally organized around four questions.

1. Effect on skin parameters. Do hydration, elasticity, texture, and radiance improve after the sessions?
2. Biological effect. Does the product stimulate fibroblasts, collagen, and the extracellular matrix, besides hydrating?
3. Satisfaction. Does the patient notice the improvement and consider it relevant?
4. Safety. What reactions occur and how often?

Each question uses different instruments, and the weak point is usually the same: it is rarely known whether the measured effect has clinical relevance for the patient.

What objective measures are used?

The table organizes the most common measures, without giving values. Each instrument measures one specific thing and does not speak for "skin quality" as a whole.

Objective measures provide precision, and scales and questionnaires provide relevance for the patient. The ideal is to combine both.

What are the most common methodological limits?

When reading a skin booster study, a few points call for attention.

• Small sample. Many studies have only a few dozen participants, which reduces the ability to detect differences and to generalize.
• No control. "Before and after" studies without a comparison group do not separate the effect of the product from the effect of time, the care routine, and expectation.
• Insufficient blinding. When the evaluator knows what was injected, the risk of bias increases.
• Short follow-up. Many follow patients for only a few months, and what happens afterward is less well known.
• Different products and techniques. Each study uses a different gel, concentration, and technique; pooling them is risky.
• Subjective outcomes. Satisfaction and observer scales depend on perception.
• Conflict of interest. Studies funded by manufacturers call for critical reading, which does not make them invalid.
• Publication bias. Positive results tend to be published more than neutral ones; see publication bias in aesthetics.

The page levels of evidence in facial harmonization explains the hierarchy of study designs, and how to read a clinical trial of injectables offers a roadmap.

What does the literature usually describe?

In qualitative terms, and without citing numbers, the most frequent findings in the literature are the following:

• Improved hydration and skin appearance in some patients, generally gradual and subtle.
• Possible improvement in elasticity in some studies, with wide variation between them.
• Signs of an effect on fibroblasts and the extracellular matrix in laboratory studies and small series, whose clinical translation is still debated.
• A safety profile generally considered favorable, with frequent local reactions and uncommon serious complications; see skin booster complications.
• Little protocol standardization, with many variations in product, volume, and interval.

All of this points to a reasonable use with moderate expectations. The data do not support promises of "rejuvenation" or of lasting effects without maintenance.

How does hydrophilicity enter the conversation?

Part of the argument for the skin booster is hyaluronic acid's ability to retain water (hydrophilicity). That mechanism is real, but explaining the result by it alone is an oversimplification. The short-term effect, hydration, is different from the medium-term effect, possible cell stimulation, and neither is equivalent to a volumizing filler. It is worth explaining it this way to the patient and avoiding slogans such as "deep hydration," which suggest more than is known.

How do you apply this in the consultation?

The way to translate evidence for the patient is balance: neither exaggerating nor dismissing what the literature points to.

A short list helps keep the conversation honest.

For communication, the advertising rule also applies: numbers and comparisons in public material follow the rules of your professional council and CONAR (Brazil's advertising self-regulation body); see what you may advertise.

How do you keep up with the literature?

The field moves fast. A few routines help you stay up to date without getting lost in the noise: follow systematic reviews, read the study design carefully before the results, be wary of overly enthusiastic conclusions, and take part in study groups. The page how to keep up with the scientific literature goes into detail. And when citing studies to colleagues or patients, always state the type of study and its limitations.

How Harmy fits in

Harmy is not a clinical evidence tool and does not simulate a skin booster. The projection is visual, of volume and contour, and should be treated as an illustration. The honesty that applies to studies applies to the image: say what it shows and what it does not.

Key takeaways

The evidence on skin boosters is real but limited: small, heterogeneous, short-duration studies, with outcomes that do not always reflect what the patient perceives. Read the design before the results, distinguish objective measures from perception, avoid invented numbers, and translate the knowledge for the patient with moderate expectations.